13 completed, 7 terminated, 3 unknown, 1 withdrawn. 16 Phase 2, 4 Phase 4, 3 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 7, Terminated 6, Unknown 2, Withdrawn 1 |
| Phase 4 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Exjade: new trials by email Literature Review of Exjade trials Research Report on Exjade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease Deferasirox 360 MG - Sickle Cell Disease | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 12 | 2021-07-20 | 2023-02-13 |
| Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS Deferasirox - Myelodysplastic Syndromes | Phase 2 | Terminated | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 11 | 2019-10-04 | 2022-11-21 |
| Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation DST-0509, Jadenu, Exjade - Thalassemia Major | Phase 2 | Completed | DisperSol Technologies, LLC | 25 | 2019-08-20 | 2022-02-01 |
| Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents Deferasirox - Myelodysplasia | Phase 2 | Completed | University Hospital, Grenoble | 39 | 2018-02-20 | 2024-12-16 |
| Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome Deferasirox, Laboratory Biomarker Analysis - Anemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 2 | 2017-03-02 | 2020-07-01 |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation EXJADE - Myeloid Leukemia, Myelodysplastic Syndromes | Unknown | Hospices Civils de Lyon | 150 | 2016-04-01 | 2018-09-06 | |
| Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) Deferasirox + Azacitidine, Azacitidine - Myelodysplastic Syndromes | Phase 2 | Terminated | Sunnybrook Health Sciences Centre | 1 | 2014-03-01 | 2018-04-26 |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome Deferasirox, Venesection - Hemochromatosis, Myelodysplastic Syndromes | Phase 2 | Withdrawn | Haukeland University Hospital | 2013-05-01 | 2024-04-03 | |
| A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS Deferasirox, Vitamin D and Azacitidine - MDS | Phase 1 / Phase 2 | Unknown | Groupe Francophone des Myelodysplasies | 50 | 2013-02-01 | 2018-01-10 |
| Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 Deferasirox, Cholecalciferol, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Terminated | Elizabeth Henry | 4 | 2013-02-01 | 2020-02-27 |
| Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia Deferasirox and deferiprone - Thalassemia Major With Severe Transfusional Iron Overload | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 9 | 2012-09-01 | 2019-03-06 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda Exjade - Porphyria Cutanea Tarda | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 45 | 2011-01-01 | 2011-01-27 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis Exjade - Non-alcoholic Steatohepatitis, Increased Iron Storage / Disturbed Distribution | Phase 1 / Phase 2 | Completed | Crolll Gmbh | 5 | 2010-03-01 | 2012-07-20 |
| Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia iron sucrose, Deferasirox, endotoxin - Systemic Inflammatory Process, Anemia | Not applicable | Completed | Radboud University Medical Center | 30 | 2010-02-01 | 2015-11-17 |
| Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food deferasirox: - Transfusional Hemosiderosis | Phase 4 | Completed | Novartis Pharmaceuticals | 65 | 2009-05-01 | 2021-07-20 |
| Clinical Importance of Treating Iron Overload in Sickle Cell Disease deferasirox - Anemia, Sickle Cell, Transfusion Hemosiderosis | Phase 3 | Terminated | Children's Hospital Los Angeles | 1 | 2009-04-01 | 2017-02-08 |
| Pilot Study for Patients With Poor Response to Deferasirox Deferoxamine, Deferasirox, HIDA - Transfusion-dependent Hemachromatosis, Thalassemia Major | Phase 4 | Completed | Boston Children's Hospital | 15 | 2008-03-01 | 2024-02-12 |
| Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda Deferasirox - Porphyria Cutanea Tarda | Phase 3 | Completed | University of Texas Southwestern Medical Center | 10 | 2008-01-01 | 2014-02-10 |
Showing 20 of 24. Sign in to see all of them.
Myelodysplastic Syndromes (7) · Iron Overload (6) · Leukemia, Myeloid, Acute (4) · Anemia, Sickle Cell (3) · Multiple Myeloma (3) · Thalassemia (3) · beta-Thalassemia (3) · Anemia (2) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Congenital Abnormalities (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2)
Novartis Pharmaceuticals (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Children's Hospital (1) · Children's Hospital Los Angeles (1) · Children's Hospital of Philadelphia (1) · City of Hope Medical Center (1) · Crolll Gmbh (1) · DisperSol Technologies, LLC (1) · Elizabeth Henry (1) · Fondazione Italiana Sindromi Mielodisplastiche-ETS (1) · Fred Hutchinson Cancer Center (1) · Groupe Francophone des Myelodysplasies (1) · Haukeland University Hospital (1) · Hospices Civils de Lyon (1)
United States (12) · France (4) · Belgium (1) · Canada (1) · Egypt (1) · Germany (1) · Israel (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Norway (1) · Oman (1) · Saudi Arabia (1) · Syria (1) · Thailand (1)
Amit Pandya, M.D. (1) · Bart Scott (1) · Brad Spellberg, MD (1) · Deborah Chirnomas, MD (1) · Deybach Jean-Charles, Professor (1) · Elizabeth Henry, MD (1) · Erfan Nur, MD, PHD (1) · Felipe Suarez, MD (1) · Gerhard Treiber, PD Dr. med. (1) · Janet L Kwiatkowski, MD, MSCE (1) · Linda J. Burns, MD (1) · Mary Ann Knovich, MD (1) · Olivier Hermine, MD (1)
PMID 19724055, PMID 20226990, PMID 20421274, PMID 21937481, PMID 22911183, PMID 23637051, PMID 37975597
P30CA015704 (1)